Nachrichten zur Axsome Therapeutics Inc. Aktie

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder....…

Form 8-K Axsome Therapeutics, For: Jul 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…

Axsome (AXSM) Down on Public Offering of Common Stock

Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines....…

Form 8-K Axsome Therapeutics, For: Jun 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Shares of Axsome Therapeutics Fell Wednesday

The biopharmaceutical company announced a $225 million stock sale....…

Axsome Therapeutics prices discounted stock offering to raise $225M, shares fall

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Shares Drop 11% After Public Offering Prices

Axsome Therapeutics Shares Drop 11% After Public Offering Prices...…

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…

Axsome Therapeutics to raise capital via stock offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a…

Form 8-K Axsome Therapeutics, For: Jun 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Where Will Axsome Therapeutics Be in 3 Years?

The stock soared more than 100% last year....…

Is Axsome Therapeutics Stock a Screaming Buy?

The biotech could be staring down an enormous commercial opportunity....…

Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might…

Axsome sees peak US sales of marketed drugs of up to $3.5B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Axsome Therapeutics, For: Jun 13

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Axsome Therapeutics, For: Jun 02

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea Cognitive…

2 Unstoppable Growth Stocks to Buy in 2023 and Beyond

Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines....…

Is a Victory for Its Rivals Bad News for Axsome Therapeutics?

The biopharmaceutical companys shares have soared during the past year....…

Form 10-Q Axsome Therapeutics, For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue…

Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript

AXSM earnings call for the period ending March 31, 2023....…

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the…

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

Auvelity® 1Q 2023 net product sales of $15.7 million...…

Form 8-K Axsome Therapeutics, For: May 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics Stock: Bear vs. Bull

Axsome shares beat the bear market last year....…

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

Axsomes (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders....…

Could Axsome Therapeutics Stock Help You Become a Millionaire?

In the past five years, the stock has risen by nearly 2,400%....…

Better Growth Stock: Axsome vs. CRISPR Therapeutics

These companies are both in the early days of their growth stories....…

Is It Too Late to Buy Axsome Therapeutics Stock?

With two major catalysts in the rearview mirror, its easy to think that its too late....…

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

Axsome to host conference call and webcast on Monday, May 8, 2023, at 8:00 a.m. Eastern Time Axsome to host…

Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today

Macro headwinds are weighing on risk-laden biotech stocks today....…

Expert Ratings for Axsome Therapeutics

Latest Ratings for AXSM DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy …

Form 8-K Axsome Therapeutics, For: Mar 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Axsome Therapeutics Stock a Buy Now?

The biotech made major progress on the regulatory front last year....…

Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales

Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain....…

Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript

AXSM earnings call for the period ending December 31, 2022....…

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of -8.47% and 13.29%, respectively, for the quarter ended December 2022. Do the…

Thinking about trading options or stock in Tesla, Coinbase Global, Axsome Therapeutics, Chevron, or Walt Disney?

NEW YORK, Feb. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, COIN, AXSM, CVX, and DIS. Click…

Form 8-K Axsome Therapeutics, For: Feb 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Q1 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pharmanovia unterzeichnet Lizenzvertrag mit Axsome Therapeutics zur Vermarktung und Weiterentwicklung von Sunosi® (Solriamfetol), dem ersten Medikament seiner Klasse gegen exzessive Tagesschläfrigkeit (EDS) bei Narkolepsie und obstruktiver...

BASILDON, Großbritannien--(BUSINESS WIRE)--Pharmanovia unterzeichnet Lizenzvertrag mit Axsome Therapeutics zur Vermarktung und Weiterentwicklung von Sunosi® (Solriamfetol), dem ersten Medikament seiner Klasse…

Axsome Inks Overseas Sunosi License Deal With Pharmanovia >AXSM

Axsome Inks Overseas Sunosi License Deal With Pharmanovia >AXSM...…

dpa-AFX ProFeed